Mitry Ragai R, Hughes Robin D, Dhawan Anil
Institute of Liver Studies, King's College London School of Medicine at King's College Hospital, London, UK.
J Clin Exp Hepatol. 2011 Sep;1(2):109-14. doi: 10.1016/S0973-6883(11)60129-1. Epub 2011 Nov 9.
Hepatocyte transplantation (HTx) has been developed for use in liver-based metabolic disorders and in acute liver failure. Worldwide, there are around 80 patients that have been transplanted with hepatocytes. Almost all reported studies prove feasibility and safety of the procedure with short- to medium-term success. Availability of good quality hepatocytes (HCs) is the main limiting factor, and therefore alternative sources of cells such as stem cells are being investigated. Other limiting factors include cell engraftment, survival, and function of transplanted cells. It remains to be seen if progress in HTx research can overcome these hurdles leading to the wider use of the technique as an alternative to liver transplantation in the future.
肝细胞移植(HTx)已被开发用于治疗基于肝脏的代谢紊乱和急性肝衰竭。在全球范围内,约有80名患者接受了肝细胞移植。几乎所有已报道的研究都证明了该手术的可行性和安全性,并取得了短期至中期的成功。优质肝细胞(HCs)的可获得性是主要限制因素,因此正在研究诸如干细胞等细胞的替代来源。其他限制因素包括移植细胞的植入、存活和功能。HTx研究的进展能否克服这些障碍,从而在未来使该技术作为肝移植的替代方法得到更广泛应用,仍有待观察。